EDAP EDAP TMS SA

EDAP TMS S.A. Retains Halliburton Investor Relations as Counsel Company to Begin Enhanced Shareholder Communications and Outreach Program LYON, France, Jan. 25 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ:EDAP), today announced it has retained Halliburton Investor Relations to assist the company in its efforts to communicate with the investment community. Hugues de Bantel, Chief Executive Officer of EDAP TMS, commented: "We are pleased to move forward in sharing our corporate strategy with the professional investment community. In the last year, we have made substantial strides in our operational success, including an objective of division profitability and significant sales growth. Our new partnership with Halliburton Investor Relations will enable us to more fully communicate our success and plans for the future to a broader audience. Halliburton Investor Relations has a proven track record of successful strategic investor communications programs for publicly traded companies." Alan Halliburton, President of Halliburton Investor Relations, said: "EDAP is a successful, growing and innovative company but has remained undiscovered by the investment community. We believe the company's success in its product lines and future growth opportunities, especially the High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer where EDAP is a clear market leader, make it a prime candidate for our strategic investor relations program. With management, we will work to broaden EDAP's corporate visibility and help achieve improved liquidity as well as a proper valuation of the company's stock within the marketplace." Based in Dallas, Texas, Halliburton Investor Relations was formed in 1990 to provide a superior caliber of investor relations representation to publicly traded companies. The firm develops strategic communications programs designed to cultivate highly targeted relationships in the financial community and improve the visibility of successful public companies to investors. For more information, visit the company's Web site at http://www.halliburtonir.com/. EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. The company is also developing this technology for the treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL). For more information on the Company, contact the Investor Relations Dept by phone at +33 (0)4 78 26 40 46 or see the Company's Web site at: http://www.edap-tms.com/. This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Web sites: http://www.edap-tms.com http://www.halliburtonir.com DATASOURCE: EDAP TMS S.A. CONTACT: EDAP TMS S.A. -- Hugues de Bantel - Philippe Chauveau, Blandine Confort, +33-4-78-26-40-46, or Halliburton Investor Relations -- Matt Kreps - Geralyn DeBusk, +1-972-458-8000

Copyright